Magnesium Sulfate Torbay Pharmaceuticals (Magnesium Sulfate Heptahydrate)

Magnesium sulfate releases magnesium ions that act as calcium antagonists. By competing with calcium at voltage‑gated channels, it stabilises cell membranes, reduces neuronal excitability, relaxes smooth muscle, and diminishes the propagation of abnormal electrical activity in the heart and nervous system.

The dosing regimen for magnesium sulfate is determined by the treating physician based on the specific indication, patient weight, renal function, and clinical response. Healthcare professionals calculate the appropriate infusion rate and total dose according to established clinical guidelines.

Magnesium sulfate is commonly used in obstetric care for eclampsia prevention, but safety data are limited for other indications. In pregnancy, benefits for maternal seizure prevention generally outweigh potential fetal risks when used under obstetric supervision. Limited information is available for breastfeeding; clinicians should assess risk‑benefit before use.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Magnesium sulfate is the most widely used intravenous magnesium salt because of its high solubility and rapid bioavailability. Compared with magnesium gluconate or magnesium chloride, sulfate provides a higher elemental magnesium concentration per millilitre, making it preferred for acute correction of severe deficiency and for obstetric seizure prophylaxis.

The product should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect it from direct sunlight, moisture, and extreme temperature fluctuations. Once reconstituted, follow the manufacturer’s guidance on stability and use within the recommended time frame.

Magnesium sulfate is administered intravenously, typically as a slow infusion under continuous cardiac and blood pressure monitoring. The infusion rate is adjusted according to serum magnesium levels and clinical response, and the drug may be given as a loading dose followed by a maintenance infusion.

The most serious risks include hypermagnesemia leading to respiratory depression, cardiac arrest, severe hypotension, and life‑threatening arrhythmias. Prompt recognition of elevated serum magnesium and immediate cessation of the infusion are essential to prevent these complications.

Magnesium sulfate is contraindicated in patients with known hypersensitivity to magnesium salts, in those with severe renal failure where clearance is markedly reduced, and in individuals with existing severe hypermagnesemia. Caution is also advised for patients with myasthenia gravis or other neuromuscular disorders.